Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury

300Citations
Citations of this article
268Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Preclinical studies have attributed neuroprotective properties to the antibiotic minocycline. Animal studies and early clinical trials support its use in several neurological diseases. In animal spinal cord injury models, minocycline improved neurological and histological outcomes, reduced neuronal and oligodendroglial apoptosis, decreased microglial activation and reduced inflammation. A single-centre, human, double-blind, randomized, placebo-controlled study of minocycline administration after spinal cord injury was undertaken for the purposes of dose optimization, safety assessment and to estimate outcome changes and variance. Neurological, functional, pharmacological and adverse event outcomes were compared between subjects administered 7 days of intravenous minocycline (n = 27) or placebo (n = 25) after acute traumatic spinal cord injury. The secondary outcome used to assess neurological differences between groups that may warrant further investigation was motor recovery over 1 year using the American Spinal Cord Injury Association examination. Recruitment and analyses were stratified by injury severity and injury location a priori given the expected influence of these on the sensitivity of the motor exam. Minocycline administered at higher than previously reported human doses produced steady-state concentrations of 12.7 g/ml (95 confidence interval 11.6-13.8) in serum and 2.3 g/ml (95 confidence interval 2.1-2.5) in cerebrospinal fluid, mimicking efficacious serum levels measured in animal studies. Transient elevation of serum liver enzymes in one patient was the only adverse event likely related to the study drug. Overall, patients treated with minocycline experienced six points greater motor recovery than those receiving placebo (95 confidence interval-3 to 14; P = 0.20, n = 44). No difference in recovery was observed for thoracic spinal cord injury (n = 16). A difference of 14 motor points that approached significance was observed in patients with cervical injury (95 confidence interval 0-28; P = 0.05, n = 25). Patients with cervical motor-incomplete injury may have experienced a larger difference (results not statistically significant, n = 9). Functional outcomes exhibited differences that lacked statistical significance but that may be suggestive of improvement in patients receiving the study drug. The minocycline regimen established in this study proved feasible, safe and was associated with a tendency towards improvement across several outcome measures. Although this study does not establish the efficacy of minocycline in spinal cord injury the findings are encouraging and warrant further investigation in a multi-centre phase III trial. ClinicalTrials.gov number NCT00559494. © 2012 The Author.

References Powered by Scopus

Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia

910Citations
N/AReaders
Get full text

Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: Spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials

731Citations
N/AReaders
Get full text

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial

577Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The far-reaching scope of neuroinflammation after traumatic brain injury

727Citations
N/AReaders
Get full text

Traumatic spinal cord injury - Repair and regeneration

622Citations
N/AReaders
Get full text

Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury

425Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Casha, S., Zygun, D., McGowan, M. D., Bains, I., Yong, V. W., & John Hurlbert, R. (2012). Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. Brain, 135(4), 1224–1236. https://doi.org/10.1093/brain/aws072

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 101

68%

Researcher 34

23%

Professor / Associate Prof. 12

8%

Lecturer / Post doc 2

1%

Readers' Discipline

Tooltip

Medicine and Dentistry 64

43%

Neuroscience 44

29%

Agricultural and Biological Sciences 28

19%

Biochemistry, Genetics and Molecular Bi... 14

9%

Article Metrics

Tooltip
Mentions
News Mentions: 3

Save time finding and organizing research with Mendeley

Sign up for free